{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T15:52:12Z","timestamp":1793029932407,"version":"4.5.0"},"reference-count":87,"publisher":"Oxford University Press (OUP)","issue":"40","license":[{"start":{"date-parts":[[2019,4,19]],"date-time":"2019-04-19T00:00:00Z","timestamp":1555632000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010447","name":"DZHK","doi-asserted-by":"publisher","award":["81X2400126"],"award-info":[{"award-number":["81X2400126"]}],"id":[{"id":"10.13039\/100010447","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,10,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Heart failure with preserved ejection fraction (HFpEF) and pathological cardiac aging share a complex pathophysiology, including extracellular matrix remodelling (EMR). Protease-activated receptor 2 (PAR2) deficiency is associated with EMR. The roles of PAR1 and PAR2 have not been studied in HFpEF, age-dependent cardiac fibrosis, or diastolic dysfunction (DD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Evaluation of endomyocardial biopsies from patients with HFpEF (n\u2009=\u200914) revealed that a reduced cardiac PAR2 expression was associated with aggravated DD and increased myocardial fibrosis (r = \u22120.7336, P\u2009=\u20090.0028). In line, 1-year-old PAR2-knockout (PAR2ko) mice suffered from DD with preserved systolic function, associated with an increased age-dependent \u03b1-smooth muscle actin expression, collagen deposition (1.7-fold increase, P\u2009=\u20090.0003), lysyl oxidase activity, collagen cross-linking (2.2-fold increase, P\u2009=\u20090.0008), endothelial activation, and inflammation. In the absence of PAR2, the receptor-regulating protein caveolin-1 was down-regulated, contributing to an augmented profibrotic PAR1 and transforming growth factor beta (TGF-\u03b2)-dependent signalling. This enhanced TGF-\u03b2\/PAR1 signalling caused N-proteinase (ADAMTS3) and C-proteinase (BMP1)-related increased collagen I production from cardiac fibroblasts (CFs). PAR2 overexpression in PAR2ko CFs reversed these effects. The treatment with the PAR1 antagonist, vorapaxar, reduced cardiac fibrosis by 44% (P\u2009=\u20090.03) and reduced inflammation in a metabolic disease model (apolipoprotein E-ko mice). Patients with HFpEF with upstream PAR inhibition via FXa inhibitors (n\u2009=\u200940) also exhibited reduced circulating markers of fibrosis and DD compared with patients treated with vitamin K antagonists (n\u2009=\u200920).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Protease-activated receptor 2 is an important regulator of profibrotic PAR1 and TGF-\u03b2 signalling in the heart. Modulation of the FXa\/FIIa-PAR1\/PAR2\/TGF-\u03b2-axis might be a promising therapeutic approach to reduce HFpEF.<\/jats:p>\n                    <jats:p\/>\n                  <\/jats:sec>","DOI":"10.1093\/eurheartj\/ehz117","type":"journal-article","created":{"date-parts":[[2019,4,5]],"date-time":"2019-04-05T17:10:57Z","timestamp":1554484257000},"page":"3318-3332","source":"Crossref","is-referenced-by-count":59,"title":["Protease-activated receptor 2 deficiency mediates cardiac fibrosis and diastolic dysfunction"],"prefix":"10.1093","volume":"40","author":[{"given":"Julian","family":"Friebel","sequence":"first","affiliation":[{"name":"Department of Cardiology, Charit\u00e9 Center 11, Charit\u00e9\u2013University Medicine Berlin , Hindenburgdamm 30, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Weithauser","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Charit\u00e9 Center 11, Charit\u00e9\u2013University Medicine Berlin , Hindenburgdamm 30, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Witkowski","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Charit\u00e9 Center 11, Charit\u00e9\u2013University Medicine Berlin , Hindenburgdamm 30, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard H","family":"Rauch","sequence":"additional","affiliation":[{"name":"Institute of Pharmacology, Center of Drug Absorption and Transport, University Medicine Greifswald , Felix-Hausdorff-Str. 3, Greifswald, Germany"},{"name":"German Centre for Cardiovascular Research (DZHK), Partner Site Greifswald, Ferdinand-Sauerbruch-Str., Greifswald , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Savvatis","sequence":"additional","affiliation":[{"name":"Inherited Cardiovascular Diseases Unit, Barts Heart Centre, Barts Health NHS Trust , West Smithfield, London, UK"},{"name":"William Harvey Research Institute, Queen Mary University London, Charterhouse Square , London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"D\u00f6rner","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Charit\u00e9 Center 11, Charit\u00e9\u2013University Medicine Berlin , Hindenburgdamm 30, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Termeh","family":"Tabaraie","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Charit\u00e9 Center 11, Charit\u00e9\u2013University Medicine Berlin , Hindenburgdamm 30, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Kasner","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Charit\u00e9 Center 11, Charit\u00e9\u2013University Medicine Berlin , Hindenburgdamm 30, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Verena","family":"Moos","sequence":"additional","affiliation":[{"name":"Medical Department I, Gastroenterology, Infectious Diseases and Rheumatology, Charit\u00e9\u2013University Medicine Berlin , Hindenburgdamm 30, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"B\u00f6sel","sequence":"additional","affiliation":[{"name":"Medical Department I, Gastroenterology, Infectious Diseases and Rheumatology, Charit\u00e9\u2013University Medicine Berlin , Hindenburgdamm 30, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Gotthardt","sequence":"additional","affiliation":[{"name":"Neuromuscular and Cardiovascular Cell Biology, Max Delbr\u00fcck Center for Molecular Medicine , Berlin, Robert-R\u00f6ssle-Str. 10, Berlin, Germany"},{"name":"German Centre for Cardiovascular Research (DZHK), Partner Site Berlin , Oudenarder Stra\u00dfe 16, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H","family":"Radke","sequence":"additional","affiliation":[{"name":"Neuromuscular and Cardiovascular Cell Biology, Max Delbr\u00fcck Center for Molecular Medicine , Berlin, Robert-R\u00f6ssle-Str. 10, Berlin, Germany"},{"name":"German Centre for Cardiovascular Research (DZHK), Partner Site Berlin , Oudenarder Stra\u00dfe 16, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Wegner","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Charit\u00e9 Center 11, Charit\u00e9\u2013University Medicine Berlin , Hindenburgdamm 30, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Bobbert","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Angiology, Hubertus Hospital , Berlin, Spanische Allee 10-14, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Lassner","sequence":"additional","affiliation":[{"name":"Institute for Cardiac Diagnostics and Therapy (IKDT) , Moltkestr. 31, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Tsch\u00f6pe","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Charit\u00e9 Center 11, Charit\u00e9\u2013University Medicine Berlin , Hindenburgdamm 30, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz-Peter","family":"Schutheiss","sequence":"additional","affiliation":[{"name":"Institute for Cardiac Diagnostics and Therapy (IKDT) , Moltkestr. 31, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan B","family":"Felix","sequence":"additional","affiliation":[{"name":"German Centre for Cardiovascular Research (DZHK), Partner Site Greifswald, Ferdinand-Sauerbruch-Str., Greifswald , Germany"},{"name":"Department of Internal Medicine B, Cardiology, University Medicine Greifswald , Ferdinand-Sauerbruch-Str., Greifswald, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"Landmesser","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Charit\u00e9 Center 11, Charit\u00e9\u2013University Medicine Berlin , Hindenburgdamm 30, Berlin, Germany"},{"name":"German Centre for Cardiovascular Research (DZHK), Partner Site Berlin , Oudenarder Stra\u00dfe 16, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"Rauch","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Charit\u00e9 Center 11, Charit\u00e9\u2013University Medicine Berlin , Hindenburgdamm 30, Berlin, Germany"},{"name":"German Centre for Cardiovascular Research (DZHK), Partner Site Berlin , Oudenarder Stra\u00dfe 16, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,4,19]]},"reference":[{"key":"2022102616402654400_ehz117-B1","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/nrcardio.2017.65","article-title":"Epidemiology of heart failure with preserved ejection fraction","volume":"14","author":"Dunlay","year":"2017","journal-title":"Nat Rev Cardiol"},{"key":"2022102616402654400_ehz117-B2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00392-017-1170-6","article-title":"Heart failure with preserved ejection fraction: current management and future strategies","volume":"107","author":"Tsch\u00f6pe","year":"2018","journal-title":"Clin Res Cardiol"},{"key":"2022102616402654400_ehz117-B3","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.jacc.2016.10.078","article-title":"Mode of death in heart failure with preserved ejection fraction","volume":"69","author":"Vaduganathan","year":"2017","journal-title":"Am J Cardiol"},{"key":"2022102616402654400_ehz117-B4","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1016\/j.jacc.2017.08.074","article-title":"Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes","volume":"70","author":"Shah","year":"2017","journal-title":"Am J Cardiol"},{"key":"2022102616402654400_ehz117-B5","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1161\/CIRCULATIONAHA.116.021884","article-title":"Phenotype-specific treatment of heart failure with preserved ejection fraction. a multiorgan roadmap","volume":"134","author":"Shah","year":"2016","journal-title":"Circulation"},{"key":"2022102616402654400_ehz117-B6","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1161\/CIRCULATIONAHA.114.010637","article-title":"Phenomapping for novel classification of heart failure with preserved ejection fraction","volume":"131","author":"Shah","year":"2015","journal-title":"Circulation"},{"key":"2022102616402654400_ehz117-B7","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1161\/CIRCHEARTFAILURE.114.001583","article-title":"Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial","volume":"7","author":"Shah","year":"2014","journal-title":"Circ Heart Fail"},{"key":"2022102616402654400_ehz117-B8","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1016\/j.jacc.2017.09.006","article-title":"Biological phenotypes of heart failure with preserved ejection fraction","volume":"70","author":"Lewis","year":"2017","journal-title":"Am J Cardiol"},{"key":"2022102616402654400_ehz117-B9","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1093\/eurheartj\/ehu204","article-title":"New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes","volume":"35","author":"Senni","year":"2014","journal-title":"Eur Heart J"},{"key":"2022102616402654400_ehz117-B10","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1161\/CIRCRESAHA.116.310119","article-title":"Why don\u2019t we have proven treatments for HFpEF?","volume":"120","author":"Roh","year":"2017","journal-title":"Circ Res"},{"key":"2022102616402654400_ehz117-B11","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1093\/cvr\/cvy095","article-title":"Modelling the complexity of heart failure with preserved ejection fraction","volume":"114","author":"O'Gallagher","year":"2018","journal-title":"Cardiovasc Res"},{"key":"2022102616402654400_ehz117-B12","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/ejhf.1059","article-title":"An integrative translational approach to study heart failure with preserved ejection fraction: a position paper from the Working Group on Myocardial Function of the European Society of Cardiology","volume":"20","author":"Louren\u00e7o","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2022102616402654400_ehz117-B13","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/ejhf.696","article-title":"Myocardial fibrosis: biomedical research from bench to bedside","volume":"19","author":"Gy\u00f6ngy\u00f6si","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2022102616402654400_ehz117-B14","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1161\/CIRCHEARTFAILURE.109.931451","article-title":"Cardiac inflammation contributes to changes in the extracellular matrix in patients with heart failure and normal ejection fraction","volume":"4","author":"Westermann","year":"2011","journal-title":"Circ Heart Fail"},{"key":"2022102616402654400_ehz117-B15","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","article-title":"A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation","volume":"62","author":"Paulus","year":"2013","journal-title":"Am J Cardiol"},{"key":"2022102616402654400_ehz117-B16","doi-asserted-by":"crossref","first-page":"H1","DOI":"10.1152\/ajpheart.00335.2010","article-title":"Role of lysyl oxidase in myocardial fibrosis: from basic science to clinical aspects","volume":"299","author":"L\u00f3pez","year":"2010","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2022102616402654400_ehz117-B17","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/j.jacc.2018.02.021","article-title":"Myocardial interstitial fibrosis in heart failure: biological and translational perspectives","volume":"71","author":"Gonz\u00e1lez","year":"2018","journal-title":"Am J Cardiol"},{"key":"2022102616402654400_ehz117-B18","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1161\/CIRCHEARTFAILURE.113.000539","article-title":"Myocardial titin hypophosphorylation importantly contributes to heart failure with preserved ejection fraction in a rat metabolic risk model","volume":"6","author":"Hamdani","year":"2013","journal-title":"Circ Heart Fail"},{"key":"2022102616402654400_ehz117-B19","doi-asserted-by":"crossref","first-page":"58.","DOI":"10.1038\/cr.2008.315","article-title":"Endocytic regulation of TGF-\u03b2 signaling","volume":"19","author":"Chen","year":"2009","journal-title":"Cell Res"},{"key":"2022102616402654400_ehz117-B20","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1111\/j.1538-7836.2007.02759.x","article-title":"Tissue factor induction by protease-activated receptor 1 requires intact caveolin-enriched membrane microdomains in human endothelial cells","volume":"5","author":"Banfi","year":"2007","journal-title":"J Thromb Haemost"},{"key":"2022102616402654400_ehz117-B21","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.jacc.2010.10.024","article-title":"Diastolic tissue Doppler indexes correlate with the degree of collagen expression and cross-linking in heart failure and normal ejection fraction","volume":"57","author":"Kasner","year":"2011","journal-title":"Am J Cardiol"},{"key":"2022102616402654400_ehz117-B22","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.116.005277","article-title":"Interstitial fibrosis, functional status, and outcomes in heart failure with preserved ejection fraction: insights from a prospective cardiac magnetic resonance imaging study","volume":"9","author":"Duca","year":"2016","journal-title":"Circ Cardiovasc Imaging"},{"key":"2022102616402654400_ehz117-B23","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1001\/jamacardio.2017.2511","article-title":"Temporal relation between myocardial fibrosis and heart failure with preserved ejection fraction: association with baseline disease severity and subsequent outcome","volume":"2","author":"Schelbert","year":"2017","journal-title":"JAMA Cardiol"},{"key":"2022102616402654400_ehz117-B24","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jacc.2015.10.063","article-title":"Myocardial collagen cross-linking is associated with heart failure hospitalization in patients with hypertensive heart failure","volume":"67","author":"L\u00f3pez","year":"2016","journal-title":"Am J Cardiol"},{"key":"2022102616402654400_ehz117-B25","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.tcm.2014.06.004","article-title":"Role of protease-activated receptors for the innate immune response of the heart","volume":"24","author":"Weithauser","year":"2014","journal-title":"Trends Cardiovasc Med"},{"key":"2022102616402654400_ehz117-B26","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1253\/circj.CJ-15-1017","article-title":"Treating the unstable atherosclerotic plaque by targeting activated factor X\u2014anticoagulation and beyond","volume":"79","author":"Friebel","year":"2015","journal-title":"Circ J"},{"key":"2022102616402654400_ehz117-B27","doi-asserted-by":"crossref","first-page":"024","DOI":"10.1055\/s-2006-933337","article-title":"Emerging Insights in tissue factor-dependent signaling events","volume":"32","author":"Versteeg","year":"2006","journal-title":"Semin Thromb Hemost"},{"key":"2022102616402654400_ehz117-B28","doi-asserted-by":"crossref","first-page":"4540","DOI":"10.1096\/fj.12-213496","article-title":"Defining the cellular repertoire of GPCRs identifies a profibrotic role for the most highly expressed receptor, protease-activated receptor 1, in cardiac fibroblasts","volume":"26","author":"Snead","year":"2012","journal-title":"FASEB J"},{"key":"2022102616402654400_ehz117-B29","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1093\/eurheartj\/ehw119","article-title":"Hypercoagulability causes atrial fibrosis and promotes atrial fibrillation","volume":"38","author":"Spronk","year":"2017","journal-title":"Eur Heart J"},{"key":"2022102616402654400_ehz117-B30","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.86608","article-title":"Uncoupling of the profibrotic and hemostatic effects of thrombin in lung fibrosis","volume":"2","author":"Shea","year":"2017","journal-title":"JCI Insight"},{"key":"2022102616402654400_ehz117-B31","first-page":"328","article-title":"Direct thrombin inhibitors prevent left atrial remodeling associated with heart failure in rats","volume":"1","author":"Jumeau","year":"2016","journal-title":"J Am Coll Cardiol Basic Trans Science"},{"key":"2022102616402654400_ehz117-B32","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ijcard.2018.05.033","article-title":"Thrombin induces protease-activated receptor 1 signaling and activation of human atrial fibroblasts and dabigatran prevents these effects","volume":"271","author":"Altieri","year":"2018","journal-title":"Int J Cardiol"},{"key":"2022102616402654400_ehz117-B33","article-title":"Inflammatory biomarkers predict heart failure severity and prognosis in patients with heart failure with preserved ejection fraction: a holistic proteomic approach","volume":"10","author":"Hage","year":"2017","journal-title":"Circ Cardiovasc Genom"},{"key":"2022102616402654400_ehz117-B34","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1161\/ATVBAHA.117.310082","article-title":"PAR2 (Protease-Activated Receptor 2) deficiency attenuates atherosclerosis in mice","volume":"38","author":"Jones","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2022102616402654400_ehz117-B35","first-page":"4512","article-title":"Protease activated receptor 2 in diabetic nephropathy: a double edged sword","volume":"9","author":"Waasdorp","year":"2017","journal-title":"Am J Transl Res"},{"key":"2022102616402654400_ehz117-B36","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.yjmcc.2008.03.013","article-title":"Viral myocarditis and coagulopathy: increased tissue factor expression and plasma thrombogenicity","volume":"45","author":"Antoniak","year":"2008","journal-title":"J Mol Cell Cardiol"},{"key":"2022102616402654400_ehz117-B37","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1161\/CIR.0000000000000509","article-title":"2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America","volume":"136","author":"Yancy","year":"2017","journal-title":"Circulation"},{"key":"2022102616402654400_ehz117-B38","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"2022102616402654400_ehz117-B39","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1093\/eurheartj\/ehm037","article-title":"How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology","volume":"28","author":"Paulus","year":"2007","journal-title":"Eur Heart J"},{"key":"2022102616402654400_ehz117-B40","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.echo.2016.01.011","article-title":"Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"29","author":"Nagueh","year":"2016","journal-title":"J Am Soc Echocardiogr"},{"key":"2022102616402654400_ehz117-B41","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1016\/j.jacc.2013.05.076","article-title":"Protease-activated receptor-2 regulates the innate immune response to viral infection in a coxsackievirus B3-induced myocarditis","volume":"62","author":"Weithauser","year":"2013","journal-title":"Am J Cardiol"},{"key":"2022102616402654400_ehz117-B42","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1161\/HYPERTENSIONAHA.112.196113","article-title":"Collagen cross-linking but not collagen amount associates with elevated filling pressures in hypertensive patients with stage C heart failure potential role of lysyl oxidase","volume":"60","author":"L\u00f3pez","year":"2012","journal-title":"Hypertension"},{"key":"2022102616402654400_ehz117-B43","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1161\/CIRCULATIONAHA.107.716886","article-title":"Role of left ventricular stiffness in heart failure with normal ejection fraction","volume":"117","author":"Westermann","year":"2008","journal-title":"Circulation"},{"key":"2022102616402654400_ehz117-B44","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.yjmcc.2011.10.002","article-title":"Getting to the heart of cardiac remodeling; how collagen subtypes may contribute to phenotype","volume":"52","author":"Collier","year":"2012","journal-title":"J Mol Cell Cardiol"},{"key":"2022102616402654400_ehz117-B45","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.jacc.2006.08.062","article-title":"Diastolic dysfunction in heart failure with preserved systolic function: need for objective evidence: results from the CHARM echocardiographic substudy\u2013CHARMES","volume":"49","author":"Persson","year":"2007","journal-title":"Am J Cardiol"},{"key":"2022102616402654400_ehz117-B46","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1161\/CIRCULATIONAHA.110.011031","article-title":"Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction","volume":"124","author":"Zile","year":"2011","journal-title":"Circulation"},{"key":"2022102616402654400_ehz117-B47","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/ehf2.12049","article-title":"Heterogeneous responses of systolic and diastolic left ventricular function to exercise in patients with heart failure and preserved ejection fraction","volume":"2","author":"Kasner","year":"2015","journal-title":"ESC Heart Fail"},{"key":"2022102616402654400_ehz117-B48","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1161\/CIRCULATIONAHA.105.587519","article-title":"Myocardial structure and function differ in systolic and diastolic heart failure","volume":"113","author":"van Heerebeek","year":"2006","journal-title":"Circulation"},{"key":"2022102616402654400_ehz117-B49","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1161\/01.CIR.0000155257.33485.6D","article-title":"Cardiomyocyte stiffness in diastolic heart failure","volume":"111","author":"Borb\u00e9ly","year":"2005","journal-title":"Circulation"},{"key":"2022102616402654400_ehz117-B50","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1161\/CIRCULATIONAHA.117.028202","article-title":"Delayed repolarization underlies ventricular arrhythmias in rats with heart failure and preserved ejection fraction","volume":"136","author":"Cho","year":"2017","journal-title":"Circulation"},{"key":"2022102616402654400_ehz117-B51","doi-asserted-by":"crossref","first-page":"13710.","DOI":"10.1038\/ncomms13710","article-title":"Targeting LOXL2 for cardiac interstitial fibrosis and heart failure treatment","volume":"7","author":"Yang","year":"2016","journal-title":"Nat Commun"},{"key":"2022102616402654400_ehz117-B52","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jchf.2015.10.007","article-title":"Myocardial microvascular inflammatory endothelial activation in heart failure with preserved ejection fraction","volume":"4","author":"Franssen","year":"2016","journal-title":"JACC Heart Fail"},{"key":"2022102616402654400_ehz117-B53","doi-asserted-by":"crossref","first-page":"3770","DOI":"10.1172\/JCI94753","article-title":"Fibroblast-specific TGF-\u03b2\u2013Smad2\/3 signaling underlies cardiac fibrosis","volume":"127","author":"Khalil","year":"2017","journal-title":"J Clin Invest"},{"key":"2022102616402654400_ehz117-B54","article-title":"Myocardial fibrosis as a matter of cell differentiation: opportunities for new antifibrotic strategies","volume":"2","author":"Tsch\u00f6pe","year":"2018","journal-title":"Eur Heart J"},{"key":"2022102616402654400_ehz117-B55","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1182\/blood-2011-09-377648","article-title":"Platelet TGF-\u03b21 contributions to plasma TGF-\u03b21, cardiac fibrosis, and systolic dysfunction in a mouse model of pressure overload","volume":"119","author":"Meyer","year":"2012","journal-title":"Blood"},{"key":"2022102616402654400_ehz117-B56","doi-asserted-by":"crossref","first-page":"859","DOI":"10.2174\/156652406779010821","article-title":"Blood coagulation and alternative pre-mRNA splicing: an overview","volume":"6","author":"Vladimir","year":"2006","journal-title":"Curr Mol Med"},{"key":"2022102616402654400_ehz117-B57","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1161\/CIRCULATIONAHA.107.692764","article-title":"Protease-activated receptor-1 contributes to cardiac remodeling and hypertrophy","volume":"116","author":"Pawlinski","year":"2007","journal-title":"Circulation"},{"key":"2022102616402654400_ehz117-B58","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.stemcr.2016.10.006","article-title":"PAR1 scaffolds TGF\u03b2RII to downregulate TGF-\u03b2 signaling and activate ESC differentiation to endothelial cells","volume":"7","author":"Gong","year":"2016","journal-title":"Stem Cell Reports"},{"key":"2022102616402654400_ehz117-B59","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1182\/blood-2012-09-355958","article-title":"Matrix metalloproteases and PAR1 activation","volume":"121","author":"Austin","year":"2013","journal-title":"Blood"},{"key":"2022102616402654400_ehz117-B60","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1038\/sj.onc.1209291","article-title":"Activation of Smad signaling enhances collagenase-3 (MMP-13) expression and invasion of head and neck squamous carcinoma cells","volume":"25","author":"Leivonen","year":"2006","journal-title":"Oncogene"},{"key":"2022102616402654400_ehz117-B61","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1161\/CIRCULATIONAHA.117.028145","article-title":"Plasminogen activator inhibitor type I controls cardiomyocyte transforming growth factor-\u03b2 and cardiac fibrosis","volume":"136","author":"Flevaris","year":"2017","journal-title":"Circulation"},{"key":"2022102616402654400_ehz117-B62","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.tcb.2006.11.008","article-title":"Do caveolins regulate cells by actions outside of caveolae?","volume":"17","author":"Head","year":"2007","journal-title":"Trends Cell Biol"},{"key":"2022102616402654400_ehz117-B63","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/labinvest.2016.153","article-title":"Reversal of maladaptive fibrosis and compromised ventricular function in the pressure overloaded heart by a caveolin-1 surrogate peptide","volume":"97","author":"Pleasant-Jenkins","year":"2017","journal-title":"Lab Invest"},{"key":"2022102616402654400_ehz117-B64","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1242\/jcs.01731","article-title":"Procollagen trafficking, processing and fibrillogenesis","volume":"118","author":"Canty","year":"2005","journal-title":"J Cell Sci"},{"key":"2022102616402654400_ehz117-B65","doi-asserted-by":"crossref","first-page":"e81733.","DOI":"10.1371\/journal.pone.0081733","article-title":"Protease activated receptor-2 contributes to heart failure","volume":"8","author":"Antoniak","year":"2013","journal-title":"PLoS One"},{"key":"2022102616402654400_ehz117-B66","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1161\/HYPERTENSIONAHA.111.169417","article-title":"Tryptase\/Protease-activated receptor 2 interactions induce selective mitogen-activated protein kinase signaling and collagen synthesis by cardiac fibroblasts","volume":"58","author":"McLarty","year":"2011","journal-title":"Hypertension"},{"key":"2022102616402654400_ehz117-B67","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.dib.2018.05.124","article-title":"Data regarding the effects of thrombin and dabigatran-inhibited thrombin on protease-activated receptor 1 and activation of human atrial fibroblasts","volume":"19","author":"Altieri","year":"2018","journal-title":"Data Brief"},{"key":"2022102616402654400_ehz117-B68","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s12079-011-0146-y","article-title":"Tryptase activates isolated adult cardiac fibroblasts via protease activated receptor-2 (PAR-2)","volume":"6","author":"Murray","year":"2012","journal-title":"J Cell Commun Signal"},{"key":"2022102616402654400_ehz117-B69","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1111\/jcmm.12520","article-title":"Protease-activated receptor (PAR)-2 is required for PAR-1 signalling in pulmonary fibrosis","volume":"19","author":"Lin","year":"2015","journal-title":"J Cell Mol Med"},{"key":"2022102616402654400_ehz117-B70","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.jjcc.2017.08.007","article-title":"Possible role of rivaroxaban in attenuating pressure-overload-induced atrial fibrosis and fibrillation","volume":"71","author":"Kondo","year":"2018","journal-title":"J Cardiol"},{"key":"2022102616402654400_ehz117-B71","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1177\/1074248413485434","article-title":"Protease-activated receptor 1 inhibition by SCH79797 attenuates left ventricular remodeling and profibrotic activities of cardiac fibroblasts","volume":"18","author":"Sonin","year":"2013","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"2022102616402654400_ehz117-B72","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1161\/ATVBAHA.110.213280","article-title":"Protease-activated receptor 2 deficiency reduces cardiac ischemia\/reperfusion injury","volume":"30","author":"Antoniak","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2022102616402654400_ehz117-B73","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s00281-011-0289-1","article-title":"Protease-activated receptor 2 signaling in inflammation","volume":"34","author":"Rothmeier","year":"2012","journal-title":"Semin Immunopathol"},{"key":"2022102616402654400_ehz117-B74","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1074\/jbc.M109160200","article-title":"arrestins regulate protease-activated receptor-1 desensitization but not internalization or down-regulation","volume":"277","author":"Paing","year":"2002","journal-title":"J Biol Chem"},{"key":"2022102616402654400_ehz117-B75","doi-asserted-by":"crossref","first-page":"E1372","DOI":"10.1073\/pnas.1112482108","article-title":"Activated protein C promotes protease-activated receptor-1 cytoprotective signaling through \u03b2-arrestin and dishevelled-2 scaffolds","volume":"108","author":"Soh","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022102616402654400_ehz117-B76","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.bbadis.2012.12.013","article-title":"Coagulation and coagulation signalling in fibrosis","volume":"1832","author":"Mercer","year":"2013","journal-title":"Biochim Biophys Acta"},{"key":"2022102616402654400_ehz117-B77","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.thromres.2017.09.016","article-title":"Direct thrombin inhibition with dabigatran attenuates pressure overload-induced cardiac fibrosis and dysfunction in mice","volume":"159","author":"Dong","year":"2017","journal-title":"Thromb Res"},{"key":"2022102616402654400_ehz117-B78","doi-asserted-by":"crossref","first-page":"12931.","DOI":"10.1038\/srep12931","article-title":"Seven weeks of Western diet in apolipoprotein-E-deficient mice induce metabolic syndrome and non-alcoholic steatohepatitis with liver fibrosis","volume":"5","author":"Schierwagen","year":"2015","journal-title":"Sci Rep"},{"key":"2022102616402654400_ehz117-B79","doi-asserted-by":"crossref","first-page":"22.","DOI":"10.1186\/1423-0127-19-22","article-title":"Cardiac and vascular phenotypes in the apolipoprotein E-deficient mouse","volume":"19","author":"Vasquez","year":"2012","journal-title":"J Biomed Sci"},{"key":"2022102616402654400_ehz117-B80","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/jth.13623","article-title":"Targeting coagulation factor receptors\u2014protease-activated receptors in idiopathic pulmonary fibrosis","volume":"15","author":"Lin","year":"2017","journal-title":"J Thromb Haemost"},{"key":"2022102616402654400_ehz117-B81","doi-asserted-by":"crossref","first-page":"69.","DOI":"10.1038\/nrd3615","article-title":"Targeting proteinase-activated receptors: therapeutic potential and challenges","volume":"11","author":"Ramachandran","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"2022102616402654400_ehz117-B82","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1093\/cvr\/cvt343","article-title":"Pleiotropic effects of factor Xa and thrombin: what to expect from novel anticoagulants","volume":"101","author":"Spronk","year":"2014","journal-title":"Cardiovasc Res"},{"key":"2022102616402654400_ehz117-B83","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1056\/NEJMoa1808848","article-title":"Rivaroxaban in patients with heart failure, sinus rhythm, and coronary disease","volume":"379","author":"Zannad","year":"2018","journal-title":"N Engl J Med"},{"key":"2022102616402654400_ehz117-B84","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1161\/CIRCHEARTFAILURE.114.001725","article-title":"Quality of anticoagulation control in preventing adverse events in heart failure patients in sinus rhythm: a warfarin aspirin reduced cardiac ejection fraction trial (WARCEF) substudy","volume":"8","author":"Homma","year":"2015","journal-title":"Circ Heart Fail"},{"key":"2022102616402654400_ehz117-B85","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N Engl J Med"},{"key":"2022102616402654400_ehz117-B86","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1016\/j.amjcard.2018.08.034","article-title":"Usefulness of rivaroxaban for secondary prevention of acute coronary syndrome in patients with history of congestive heart failure (from the ATLAS-ACS-2 TIMI-51 Trial)","volume":"122","author":"Korjian","year":"2018","journal-title":"Am J Cardiol"},{"key":"2022102616402654400_ehz117-B87","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s12265-017-9756-y","article-title":"Precision medicine for heart failure with preserved ejection fraction: an overview","volume":"10","author":"Shah","year":"2017","journal-title":"J Cardiovasc Transl Res"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/40\/40\/3318\/46646770\/eurheartj_40_40_3318.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/40\/40\/3318\/46646770\/eurheartj_40_40_3318.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T12:41:39Z","timestamp":1666788099000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/40\/40\/3318\/5475492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,19]]},"references-count":87,"journal-issue":{"issue":"40","published-online":{"date-parts":[[2019,4,19]]},"published-print":{"date-parts":[[2019,10,21]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehz117","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,10,21]]},"published":{"date-parts":[[2019,4,19]]}}}